BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stewart C, Chao J, Chen YJ, Lin J, Sullivan MJ, Melstrom L, Hyung WJ, Fong Y, Paz IB, Woo Y. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019;4:42. [PMID: 31231709 DOI: 10.21037/tgh.2019.05.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen YJ, Yeh ST, Ou LH, Lin CS, Chien CT. Impact of the extent of negative lymph nodes in gastric adenocarcinoma undergoing primary surgical resection: An institutional report. J Chin Med Assoc 2021;84:428-37. [PMID: 33595989 DOI: 10.1097/JCMA.0000000000000500] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fan J, Jiang H, Sun L, Zhang Q, Liu H. Effect of Rhizoma alismatis on the expression of hub genes in the treatment of gastric cancer. Transl Cancer Res 2021;10:4087-95. [PMID: 35116706 DOI: 10.21037/tcr-21-1041] [Reference Citation Analysis]
3 Spirina LV, Avgustinovich AV, Afanas'ev SG, Cheremisina OV, Volkov MY, Choynzonov EL, Gorbunov AK, Usynin EA. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy. Curr Drug Targets 2020;21:713-21. [PMID: 31775598 DOI: 10.2174/1389450120666191127113854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Mu L, Yang F, Guo D, Li P, Zhang M. Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p. Bioengineered 2020;11:472-83. [PMID: 32250192 DOI: 10.1080/21655979.2020.1747825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
5 Wang KX, Cui TY, Yang XD, Wang GQ, Jiang QS, Sun H, Jiang NY, Yong XM, Shi CB, Ding YB, Chen XF, Fang YY. Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. Onco Targets Ther 2021;14:4859-65. [PMID: 34584426 DOI: 10.2147/OTT.S316288] [Reference Citation Analysis]